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Introduction
Chronic nonbacterial osteomyelitis (CNO) is an autoin-
flammatory bone disorder mostly affecting children and
adolescents. Chronic recurrent multifocal osteomyelitis
(CRMO) is the most severe form of CNO. It is character-
ized by recurring episodes of bone inflammation that can
last for years and may cause chronic pain, pathological
fractures, and disability. Despite recent advances in tar-
geting disease mechanisms, the exact pathophysiology of
CNO/CRMO remains unknown. Diagnosis of CNO can
be challenging, because symptoms tend to be mild and
highly variable, and is further complicated by the absence
of widely accepted diagnostic criteria and disease
biomarkers.
Objectives
The aim of our study was to determine serum biomar-
kers for the diagnosis of CRMO, discriminating CRMO
patients from healthy individuals and patients with
other inflammatory conditions (Crohn’s disease and
JIA).
Methods
Serum of treatment-naïve CRMO patients was collected
at the time of diagnosis (N=56). As controls, sera from
treatment-naïve age matched patients with Crohn’s dis-
ease (N=62) or JIA (N=27), as well as healthy individuals
(N=62) were collected. Sera were subjected to proteomic
analysis, using the Human Cytokine 25-plex Assay (Life
Technologies) on the Luminex® 200™ platform. Stan-
dard inflammation markers from our routine clinical
chemistry laboratory (CrP) were included in our analysis.
Statistical analysis was performed using non-parametric
Kruskal-Wallis tests, Mann-Whitney-U tests, and canoni-
cal discriminant analysis to test between disease and con-
trol groups.
Results
The following (9 out of 25) serum proteins were detectable
and significantly differed between groups: IL-1RA, IL-2R,
IL-6, IL-12, Eotaxin, MCP-1, MIG, MIP-1b, RANTES.
Kruskal-Wallis and Mann-Whitney U tests confirmed sig-
nificant differences between three groups: CRMO, Crohn’s
disease, and healthy controls. Biosamples from CRMO
and JIA patients were less clearly distinguishable. Multi-
component canonical discriminant analysis allowed for the
definition of algorithms differentiating between CRMO,
Crohn’s disease, and healthy controls. We failed to differ-
entiate sera from patients with JIA from CRMO samples.
However, JIA and CRMO can usually be differentiated by
their clinical presentation.
Conclusion
Our serum marker based discrimination algorithm can
discriminate CRMO patients from patients with Crohn’s
disease and healthy individuals. Though confirmation of
our findings in larger, multi-ethnical cohorts is currently
lacking, in a clinical setting this may prove useful and
valuable to differentiate between individuals with “bone
pain” and CRMO.
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